Zoetis Inc. (ZTS)
| Market Cap | 54.02B |
| Revenue (ttm) | 9.40B |
| Net Income (ttm) | 2.65B |
| Shares Out | 440.69M |
| EPS (ttm) | 5.94 |
| PE Ratio | 20.65 |
| Forward PE | 18.58 |
| Dividend | $2.00 (1.61%) |
| Ex-Dividend Date | Oct 31, 2025 |
| Volume | 5,019,883 |
| Open | 125.28 |
| Previous Close | 124.44 |
| Day's Range | 121.25 - 125.80 |
| 52-Week Range | 115.25 - 181.85 |
| Beta | 0.97 |
| Analysts | Buy |
| Price Target | 178.89 (+45.95%) |
| Earnings Date | Nov 4, 2025 |
About ZTS
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other ph... [Read more]
Financial Performance
In 2024, Zoetis's revenue was $9.26 billion, an increase of 8.33% compared to the previous year's $8.54 billion. Earnings were $2.49 billion, an increase of 6.06%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ZTS stock is "Buy." The 12-month stock price target is $178.89, which is an increase of 45.95% from the latest price.
News
Zoetis Inc. (ZTS) Discusses R&D Pipeline Progress and Strategic Vision in Animal Health Innovation Transcript
Zoetis Inc. (ZTS) Discusses R&D Pipeline Progress and Strategic Vision in Animal Health Innovation Transcript
Zoetis Highlights R&D Leadership and Long-Term Growth Opportunity at Innovation Webcast
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS), the world's leading animal health company, will host an Innovation Webcast today at 8:30 a.m. ET to provide an update...
Top 15 High-Growth Dividend Stocks For December 2025
The Top 15 High-Growth Dividend Stocks for December 2025 offer a 1.58% yield and 20.97% five-year dividend growth, appearing 33% undervalued. The watchlist's goal is a 12% long-term CAGR, with Novembe...
2 Stocks to Buy Near Their 52-Week Lows
Not all stocks are soaring, but that may provide opportunity for long-term investors. Pinterest is hitting a lot of the right notes that could set it up for long-term success.
Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Lenivia® (izenivetmab) for the re...
Zoetis Osteoarthritis Pain Franchise Needs A Reset: Analyst
As the animal health industry navigates a rapidly evolving landscape, companies are increasingly challenged to maintain their competitive edge through innovation and strategic adaptation.
Zoetis to Participate in the Piper Sandler 37th Annual Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 9:30 a.m. ET. ...
Zoetis to Host Innovation Webcast
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host an Innovation Webcast at 8:30 a.m. ET on Tuesday, December 2, 2025, featuring Kristin Peck, Chief Executive O...
2 Outstanding Dividend Stocks That Are Too Cheap to Ignore
Both stocks trade at once-in-a-decade low valuations and have all-time high dividend yields. Each company leads in its niche, but both are battling through minor challenges.
Zoetis: A High-Quality Compounder Now On Sale?
Zoetis (ZTS) the world's largest animal-health company, develops and manufactures medicines, vaccines, and diagnostics for both pets and livestock. The stock has come under pressure in recent months a...
Zoetis: Why I'm Still Holding The Stock But Advise Against New Positions
Zoetis faces ongoing headwinds as Librela sales disappoint, triggering a sharp post-earnings sell-off and continued stock weakness. Librela's decline, fueled by social media concerns about side effect...
Zoetis Remains A Strong Buy Following Market Overreaction To Q3 Earnings
Zoetis Inc. is trading at historically low valuations despite continued EPS and margin growth, following a sharp post-earnings selloff. ZTS's Q3 results showed resilient profitability, but weaker guid...
3 Dividend Stocks Down 11%, 29%, and 41% to Buy in November
AbbVie continues to enjoy strong growth from its new blockbuster drugs, Rinvoq and Skyrizi. Colgate-Palmolive is a rock-solid dividend growth stock simply out of fashion amid the tech craze.
Zoetis Inc. (ZTS) Q3 2025 Earnings Call Transcript
Zoetis Inc. ( ZTS) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Steven Frank - Vice President of Investor Relations Kristin Peck - CEO & Director Wetteny Joseph - Executive...
Zoetis Stock Outlook Clouded By Rising Competitive Pressures
Animal health firm Zoetis Inc. (NYSE:ZTS) on Tuesday reported a third-quarter 2025 adjusted earnings per share of $1.70.
Zoetis: No Longer A Growth Stock
Zoetis shares have underperformed, falling over 25% in the past year, with recent guidance disappointing investors. Organic growth is slowing, especially in the United States, as core products reach m...
This Animal Health Stock Tanks on Earnings. Pig and Chicken Medication Revenue Slumps.
Zoetis slashes its full-year outlook.
Zoetis trims annual revenue forecast on muted demand for animal treatments, shares slide
Animal healthcare company Zoetis on Tuesday trimmed its annual revenue forecast on expectations of softer demand for its medicines and vaccines for pets and livestock, sending its shares down over 13%...
Zoetis Announces Third Quarter 2025 Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2025. The company reported revenue of $2.4 billion for th...
Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today announced that following a 10-year distinguished career dedicated to advancing veterinary medicine and innovatio...
Zoetis: High-Quality Compounder For Patient Long-Term Dividend Growth Investors
Zoetis is a US-based company involved in the discovery, development, manufacture, and marketing of animal medicines and vaccines. ZTS has increased its dividend for 13 consecutive years. This streak i...
2 Magnificent Dividend Stocks to Buy and Hold Forever
Investing in strong dividend stocks is a great way to earn better-than-average long-term returns. AbbVie has a reliable, non-cyclical business and a long and impressive track record of dividend growth...
Buy Zoetis Stock Today?
Zoetis (ZTS) stock warrants your attention. Why? Because it offers high margins – indicative of pricing power and the ability to generate cash – at a discounted price.
Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Portela becomes first mAb therapy with a three-month dosing interval approved for the alleviation of pain associated with OA in cats.